Shares of IPG Photonics IPGP have gained 36.7% in the year-to-date period, outperforming the broader Zacks Computer and Technology sector's 12.1% growth. The outperformance can be attributed to the company’s strategic initiatives and improving market conditions across welding, cutting, marking, medical applications and advanced technologies, such as directed energy systems.
The strategic focus on developing innovative lasers and photonic solutions to expand into medical micromachining and advanced applications bodes well for IPGP.
The company’s strategic expansion into the medical market has been a key catalyst. In the first quarter of 2026, IPGP reported significant year-over-year growth in medical revenues, driven by sales to a new customer and the continued delivery of clinically meaningful outcomes.
IPGP Expands Portfolio Through Acquisitions
IPGP’s expansion in the medical market through acquisitions and innovation has been noteworthy. In July 2026, the company announced a binding offer to acquire Lumibird Medical for €300 million, plus an earnout of up to €50 million, marking a significant expansion into higher-growth medical applications. The transaction combines IPGP's leadership in urology lasers with Lumibird Medical's strong ophthalmology franchise, creating a broader medical laser platform. The deal is expected to expand IPGP's addressable market by nearly $1 billion and be accretive to gross margin, EBITDA and adjusted earnings per share.
IPG Photonics Corporation Price and Consensus
IPG Photonics Corporation price-consensus-chart | IPG Photonics Corporation Quote
The acquisition reinforces IPGP's Advanced Solutions strategy, which targets approximately $5 billion in higher-growth medical, semiconductor, defense and scientific markets. The transaction broadens its healthcare portfolio, reduces reliance on cyclical industrial markets and accelerates its transition toward higher-value laser systems and application-specific solutions.
IPGP Benefits From Growing Medical & Semiconductor Demand
The Lumibird Medical acquisition builds on strong momentum in IPGP's medical business. A strong 2026 medical backlog and several expected product launches in 2026 and 2027 indicate continued momentum. The addition of Lumibird Medical's ophthalmology portfolio to the company's established urology business further expands its healthcare customer base and strengthens one of its fastest-growing end markets.
Beyond healthcare, IPGP continues to benefit from rising semiconductor demand driven by AI infrastructure investments, graphics processing unit (GPU) deployments and high-bandwidth memory production. The company is gaining traction with leading semiconductor equipment manufacturers across lithography, metrology and inspection applications, creating another long-term growth opportunity.
IPGP's Strong Q2 2026 Outlook
IPGP's expanding medical business, improving semiconductor exposure and continued innovation across industrial laser applications position the company for sustained long-term growth.
For the second quarter of 2026, IPGP expects revenues to be between $260 and $290 million.
The Zacks Consensus Estimate for second-quarter 2026 revenues is pegged at $279.17 million, indicating year-over-year growth of 11.35%.
The consensus estimate for second-quarter 2026 earnings is pegged at 40 cents per share, unchanged over the past 30 days, indicating year-over-year growth of 33.33%.
IPGP's Zacks Rank & Stocks to Consider
Currently, IPG Photonics carries a Zacks Rank #3 (Hold).
Digital Turbine APPS, Dell Technologies DELL and Analog Devices ADI are some better-ranked stocks that investors can consider in the broader Zacks Computer and Technology sector. Digital Turbine, Dell Technologies and Analog Devices sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
APPS shares have rallied 66.8% in the year-to-date period. The long-term earnings growth rate for Digital Turbine is pegged at 18.98%.
DELL shares have surged 203.3% in the year-to-date period. The long-term earnings growth rate for Dell Technologies is pegged at 26.35%.
Shares of ADI have gained 37.3% in the year-to-date period. The long-term earnings growth rate for Analog Devices is pegged at 28.76%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IPG Photonics Corporation (IPGP): Free Stock Analysis Report
Analog Devices, Inc. (ADI): Free Stock Analysis Report
Dell Technologies Inc. (DELL): Free Stock Analysis Report
Digital Turbine, Inc. (APPS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).